Inventor · disambiguated record
Gordon J. Freeman
Also filed as: FREEMAN GORDON · FREEMAN GORDON J · FREEMAN GORDON JAMES
91 granted patents·45 pending applications·5,090 citations·filing 1976–2025
99Inventor score
Files withDANA FARBER CANCER INST INC61NOVARTIS AG21UNIV EMORY8BRIGHAM & WOMENS HOSPITAL5HARVARD COLLEGE5
Top patents by PatentIndex Score
136 records- 0199US9683048B2Antibody molecules to PD-1 and uses thereofNOVARTIS AG·Filed 2015·Granted Jun 20, 2017·115 cites·144 claims
- 0299US7101550B2PD-1, a receptor for B7-4, and uses thereforGENETICS INST LLC·Filed 2002·Granted Sep 5, 2006·203 cites·5 claims
- 0399US6808710B1Downmodulating an immune response with multivalent antibodies to PD-1GENETICS INST·Filed 2000·Granted Oct 26, 2004·649 cites·9 claims
- 0499US5858358AMethods for selectively stimulating proliferation of T cellsUS NAVY·Filed 1994·Granted Jan 12, 1999·885 cites·33 claims
- 0598US10981990B2Antibody molecules to TIM-3 and uses thereofNOVARTIS AG·Filed 2020·Granted Apr 20, 2021·11 cites·30 claims
- 0698US9815898B2Antibody molecules to PD-1 and uses thereofNOVARTIS AG·Filed 2017·Granted Nov 14, 2017·35 cites·30 claims
- 0798US9605070B2Antibody molecules to TIM-3 and uses thereofNOVARTIS AG·Filed 2015·Granted Mar 28, 2017·67 cites·85 claims
- 0898US9102727B2Human anti-PD-1 antibodies and uses thereforDANA FARBER CANCER INST INC·Filed 2013·Granted Aug 11, 2015·181 cites·21 claims
- 0998US7638492B2Methods of upmodulating an immune response with non-activating forms of B7-4DANA FARBER CANCER INST INC·Filed 2006·Granted Dec 29, 2009·64 cites·7 claims
- 1098US5942607AB7-2: a CTLA4/CD28 ligandDANA FARBER CANCER INST INC·Filed 1993·Granted Aug 24, 1999·106 cites·9 claims
- 1197US10851165B2Antibody molecules to PD-L1 and methods of treating cancerNOVARTIS AG·Filed 2018·Granted Dec 1, 2020·10 cites·80 claims
- 1297US9988452B2Antibody molecules to PD-L1 and uses thereofNOVARTIS AG·Filed 2015·Granted Jun 5, 2018·30 cites·27 claims
- 1397US8552154B2Anti-PD-L1 antibodies and uses thereforFREEMAN GORDON J·Filed 2009·Granted Oct 8, 2013·460 cites·12 claims
- 1497US7709214B2Methods for upregulating an immune response with agents that inhibit the intereaction between PD-L2 and PD-1DANA FARBER CANCER INST INC·Filed 2007·Granted May 4, 2010·153 cites·8 claims
- 1597US7635757B2B7-4 Antibodies and uses thereforDANA FARBER CANCER INST INC·Filed 2006·Granted Dec 22, 2009·267 cites·13 claims
- 1697US6936704B1Nucleic acids encoding costimulatory molecule B7-4DANA FARBER CANCER INST INC·Filed 2000·Granted Aug 30, 2005·121 cites·64 claims
- 1796US10752687B2Antibody molecules to PD-1 and uses thereofNOVARTIS AG·Filed 2017·Granted Aug 25, 2020·6 cites·90 claims
- 1896US10011656B2Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses thereforDANA FARBER CANCER INST INC·Filed 2015·Granted Jul 3, 2018·24 cites·11 claims
- 1996US7105328B2Methods for screening for compounds that modulate pd-1 signalingWYETH CORP·Filed 2002·Granted Sep 12, 2006·144 cites·6 claims
- 2096US7038013B2B7-4 polypeptides and uses thereforDANA FABER CANCER INST INC·Filed 2001·Granted May 2, 2006·88 cites·14 claims
- 2196US5861310ATumor cells modified to express B7-2 with increased immunogenicity and uses thereforDANA FARBER CANCER INST INC·Filed 1995·Granted Jan 19, 1999·97 cites·10 claims
- 2295US11155620B2Method of detecting TIM-3 using antibody molecules to TIM-3NOVARTIS AG·Filed 2019·Granted Oct 26, 2021·6 cites·20 claims
- 2395US8101176B2Compositions and methods related to TIM-3, a TH1-specific cell surface moleculeKUCHROO VIJAY K·Filed 2008·Granted Jan 24, 2012·46 cites·20 claims
- 2495US7700301B2Methods for screening for compounds that modulate PD-1 signalingDANA FARBER CANCER INST INC·Filed 2006·Granted Apr 20, 2010·32 cites·3 claims
- 2595US7432059B2Methods of identifying compounds that upmodulate T cell activation in the presence of a PD-1 mediated signalDANA FARBER CANCER INST INC·Filed 2001·Granted Oct 7, 2008·119 cites·13 claims
- 2694US11827704B2Antibody molecules to PD-1 and uses thereofNOVARTIS AG·Filed 2020·Granted Nov 28, 2023·2 cites·43 claims
- 2794US9845356B2Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of useDANA FARBER CANCER INST INC·Filed 2013·Granted Dec 19, 2017·21 cites·30 claims
- 2894US9457080B2Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathwayUNIV EMORY·Filed 2013·Granted Oct 4, 2016·31 cites·16 claims
- 2994US9333256B2Methods related to TIM 3, a Th1-specific cell surface molecule, for activating antigen presenting cellsBRIGHAM & WOMENS HOSPITAL·Filed 2014·Granted May 10, 2016·21 cites·10 claims
- 3094US8709412B2Modulation of TIM receptor activity in combination with cytoreductive therapyJONES JENNIFER·Filed 2011·Granted Apr 29, 2014·34 cites·6 claims
- 3194US7722868B2Agents that modulate the interaction of B7-1 polypeptide with PD-L1 and methods of use thereofDANA FARBER CANCER INST INC·Filed 2006·Granted May 25, 2010·116 cites·7 claims
- 3294US7619078B2Nucleic acid molecules encoding B7-1DANA FARBER CANCER INST INC·Filed 2006·Granted Nov 17, 2009·17 cites·6 claims
- 3394US7470428B2Compositions and methods related to TIM-3, a Th1-specific cell surface moleculeBRIGHAM & WOMENS HOSPITAL·Filed 2003·Granted Dec 30, 2008·59 cites·10 claims
- 3494US6719972B1Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodiesREPLIGEN CORP·Filed 1994·Granted Apr 13, 2004·126 cites·11 claims
- 3593US10472419B2Antibody molecules to TIM-3 and uses thereofNOVARTIS AG·Filed 2017·Granted Nov 12, 2019·12 cites·57 claims
- 3693US9884913B2Antibody molecules to TIM-3 and uses thereofNOVARTIS AG·Filed 2017·Granted Feb 6, 2018·12 cites·30 claims
- 3793US8697069B2Methods related to TIM 3, a Th1-specific cell surface molecule, for activating antigen presenting cellsKUCHROO VIJAY K·Filed 2011·Granted Apr 15, 2014·22 cites·11 claims
- 3893US8652465B2Methods and compositions for the treatment of persistent infectionsFREEMAN GORDON·Filed 2006·Granted Feb 18, 2014·61 cites·26 claims
- 3993US6130316AFusion proteins of novel CTLA4/CD28 ligands and uses thereforeDANA FARBER CANCER INST INC·Filed 1994·Granted Oct 10, 2000·64 cites·69 claims
- 4090US10370448B2Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses thereforDANA FARBER CANCER INST INC·Filed 2018·Granted Aug 6, 2019·5 cites·18 claims
- 4190US2025066479A1Antibody molecules to pd-1 and uses thereofNOVARTIS AG·Filed 2024·Application pending·0 cites
- 4289US7700102B2Nucleic acids encoding CD100 moleculesDANA FARBER CANCER INST INC·Filed 2002·Granted Apr 20, 2010·23 cites·6 claims
- 4389US6608180B2B7-specific antibodiesBRIGHAM & WOMENS HOSPITAL·Filed 2001·Granted Aug 19, 2003·12 cites·2 claims
- 4488US5858776ATumor cells with increased immunogenicity and uses thereforHARVARD COLLEGE·Filed 1993·Granted Jan 12, 1999·60 cites·18 claims
- 4587US7195758B2Methods of inducing a T cell mediated immune response by administering antigen presenting B cellsDANA FARBER CANCER INST INC·Filed 2002·Granted Mar 27, 2007·21 cites·5 claims
- 4687US6605279B2Therapeutic compositions for inhibiting the interactions of B7-1 and B7-2 with their natural ligandsGENETICS INST·Filed 1999·Granted Aug 12, 2003·43 cites·6 claims
- 4787US6218510B1B7-1 and B7-2 polypeptidesBRIGHAM & WOMAN S HOSPITAL·Filed 1994·Granted Apr 17, 2001·35 cites·12 claims
- 4886US11413340B2Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapyNOVARTIS AG·Filed 2016·Granted Aug 16, 2022·2 cites·32 claims
- 4986US10934353B2Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of useDANA FARBER CANCER INST INC·Filed 2017·Granted Mar 2, 2021·2 cites·20 claims
- 5086US10202454B2Anti-PD-L1 monoclonal antibodies and fragments thereofDANA FARBER CANCER INST INC·Filed 2014·Granted Feb 12, 2019·4 cites·19 claims
Showing the top 50 of 136 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →